



Article

AmOct α 2R: Functional Characterization of a Honeybee Octopamine Receptor Inhibiting Adenylyl Cyclase Activity

Wolfgang Blenau ¹ , Joana Alessandra Wilms ², Sabine Balfanz ² and Arnd Baumann ^{2,*}

¹ Institute of Biochemistry, Leipzig University, 04103 Leipzig, Germany; wolfgang.blenau@uni-leipzig.de

² Institute of Biological Information Processing, IBI-1, Research Center Jülich, 52428 Jülich, Germany; j.wilms@gmx.de (J.A.W.); s.balfanz@fz-juelich.de (S.B.)

* Correspondence: a.baumann@fz-juelich.de; Tel.: +49-2461-614-014

Received: 14 July 2020; Accepted: 6 December 2020; Published: 8 December 2020



Abstract: The catecholamines norepinephrine and epinephrine are important regulators of vertebrate physiology. Insects such as honeybees do not synthesize these neuroactive substances. Instead, they use the phenolamines tyramine and octopamine for similar physiological functions. These biogenic amines activate specific members of the large protein family of G protein-coupled receptors (GPCRs). Based on molecular and pharmacological data, insect octopamine receptors were classified as either α - or β -adrenergic-like octopamine receptors. Currently, one α - and four β -receptors have been molecularly and pharmacologically characterized in the honeybee. Recently, an α_2 -adrenergic-like octopamine receptor was identified in *Drosophila melanogaster* (DmOct α 2R). This receptor is activated by octopamine and other biogenic amines and causes a decrease in intracellular cAMP ([cAMP]_i). Here, we show that the orthologous receptor of the honeybee (AmOct α 2R), phylogenetically groups in a clade closely related to human α_2 -adrenergic receptors. When heterologously expressed in an eukaryotic cell line, AmOct α 2R causes a decrease in [cAMP]_i. The receptor displays a pronounced preference for octopamine over tyramine. In contrast to DmOct α 2R, the honeybee receptor is not activated by serotonin. Its activity can be blocked efficiently by 5-carboxamidotryptamine and phentolamine. The functional characterization of AmOct α 2R now adds a sixth member to this subfamily of monoaminergic receptors in the honeybee and is an important step towards understanding the actions of octopamine in honeybee behavior and physiology.

Keywords: biogenic amines; cellular signaling; GPCR; honeybee; second messenger

1. Introduction

The phenolamines tyramine and octopamine act as neurotransmitters, neuromodulators, and/or neurohormones in insects as well as other protostomes and play a significant role in the regulation of physiology and behavior of these animals (for recent reviews, see [1–6]). During the last decades, the honeybee (*Apis mellifera* (*A. mellifera*)) has become established as an important model organism for investigating the roles of biogenic amines on behavioral plasticity [7–12] and social behavior [13–15]. Physiologically, octopamine and tyramine are often considered to act similarly in the honeybee [16–18]. However, there is growing evidence for distinct effects of these two closely related amines on behavior in the bee [13,19,20] and the vinegar fly *Drosophila melanogaster* (*D. melanogaster*) [21–26]. Whether and how these effects can be traced back to the repertoire and the signaling capabilities of individual receptors is a challenging question.

Like other biogenic amines, tyramine and octopamine exert their actions by binding to the members of the superfamily of G protein-coupled receptors (GPCRs). For each phenolamine, there are multiple

receptor subtypes that couple to various intracellular signaling pathways in a receptor subtype specific manner. In the honeybee, two tyramine receptors have been examined functionally so far. The AmTAR1 receptor (previously named AmTYR1) inhibits adenylyl cyclase activity and thus leads to a reduction in $[cAMP]_i$ [27–29]. More recently, a second tyramine receptor, AmTAR2, has been characterized that specifically induces cAMP production upon activation [30]. The family of octopamine receptors in the honeybee is more complex [31,32]. At the cellular level, these receptors evoke Ca^{2+} release from intracellular stores (AmOct α R, previously named AmOA1 [31]) or activate adenylyl cyclases, thereby increasing $[cAMP]_i$ (AmOct β R1–4 [32]). Recently, a novel octopamine receptor subtype was characterized in the rice stem borer, *Chilo suppressalis* (*C. suppressalis*; CsOct α 2R = CsOA3 [33]) and *D. melanogaster* (DmOct α 2R; CG18208 [34]). Interestingly, the activation of DmOct α 2R resulted in inhibition of forskolin-stimulated cAMP synthesis [34]. Thus, a signaling pathway is activated that was formerly not known to be used by octopamine. In addition, DmOct α 2R displays an unusual pharmacological profile and is also activated by tyramine and the indoleamine serotonin in a dose-dependent manner [34].

A gene potentially encoding an α_2 -adrenergic-like octopamine receptor was also identified in the honeybee genome [33–35]. The aim of the current study was to molecularly and pharmacologically characterize this AmOct α 2R receptor. Therefore, upon cloning the complete coding sequence from honeybee brain cDNA, we constitutively expressed AmOct α 2R in a cell line and examined its coupling to intracellular second messengers and its pharmacological properties. Intriguingly, receptor activation with octopamine led to a decrease in $[cAMP]_i$. We showed that AmOct α 2R had a clear preference for octopamine over tyramine (~30-fold difference in half-maximal reduction of cAMP levels (EC_{50})). In contrast to DmOct α 2R, however, AmOct α 2R was not activated by serotonin. We concluded that in vivo effects of octopamine on second messenger signaling depended on the tissue- and cell-type-specific expression patterns of the various receptor subtypes and, additionally, on potential cross-activation of tyramine receptors.

2. Results

2.1. Molecular and Structural Properties of AmOct α 2R

The amino acid sequence of a potential α_2 -adrenergic-like octopamine receptor from the honeybee has been annotated in previous studies [33–35]. Here, we have cloned the complete cDNA-encoding AmOct α 2R by PCR on single-stranded cDNA synthesized on mRNA of adult worker bee brains. The cDNA contained an open reading frame (ORF) of 2223 bp. The corresponding gene was located on chromosome LG15 (see NCBI: NC_007084.3) and consisted of three exons (Supplementary Figure S1 and Table S1).

The deduced amino acid sequence consisted of 741 residues with a calculated molecular weight of 80.7 kDa. The hydrophobicity profile according to Kyte and Dolittle [36] and the prediction of transmembrane (TM) helices using TMHMM Server v.2.0 [37] suggested seven TM domains (Figure 1a,b), which is a characteristic feature of GPCRs. The TM segments were flanked by an extracellular N-terminus of 263 residues and a short intracellular C-terminus of 14 residues. We submitted the AmOct α 2 sequence to Phyre2 [38] and obtained a three-dimensional model of the receptor. In this model, the N-terminus was almost unstructured and loosely attached to the TM domains eventually crossing the membrane as an eighth TM segment. We, therefore, omitted the first 217 residues of the primary structure and recalculated the model from residue 218 to 741. This was revealed in the typical membrane arrangement of a GPCR (Figure 1c).

The sequence of AmOct α 2R contained several putative sites for posttranslational modification (Supplementary Figure S2). Four potential N-glycosylation sites (N-X-(S/T)) were present in the extracellular N-terminus: N₂₇MT, N₁₆₄NT, N₂₃₈GS, and N₂₄₃ET. Conserved cysteine residues (C₃₃₆ and C₄₁₄) in the first and second extracellular loops might form a disulfide bridge as found in other biogenic amine receptors [39]. Five consensus sites for phosphorylation by protein kinase C and one consensus

site for phosphorylation by protein kinase A were found in the cytoplasmic domains of the receptor protein (Supplementary Figure S2).




Figure 1. Structural characteristics of the amino acid sequence deduced for AmOct α 2R. (a) Hydrophobicity profile of AmOct α 2R. The profile was calculated according to the algorithm of Kyte and Doolittle [36] using a window size of 19 amino acids. Peaks with scores greater than 1.6 (dashed line) indicate possible transmembrane (TM) regions; (b) prediction of TM domains with TMHMM server v. 2.0 [37]. Putative TM domains are indicated in red. Extracellular regions are shown with a purple line, and intracellular regions are shown with a blue line; (c) color-coded (rainbow) three-dimensional (3D) model of the receptor as predicted by Phyre2 [38]. The extracellular N-terminus (N) and the intracellular C-terminus (C) are labeled. Note that the first 216 amino acid residues of AmOct α 2R were omitted in this simulation.

In addition to these sites, several cognate sequence motifs of GPCRs were identified in the primary structure of AmOct α 2R. The D₃₆₀RY motif (D^{3.49}R^{3.50}Y^{3.51}; labeled according to [40]) was located at the cytoplasmic end of TM3. In TM7, the residues N₇₂₀PFIY (N^{7.49}P^{7.50}F^{7.51}I^{7.52}Y^{7.53}) constituted part of

the hydrophobic interaction site with the phenyl moiety of the biogenic amine. Furthermore, residues that most likely bound to the ligand (e.g., D₃₄₃ (D^{3.32}) and S_{426/430} (S^{5.42/5.46})) were highly conserved within the family of biogenic amine receptors [41].

The phylogenetic relationship of the AmOct α 2R receptor was examined using MEGA7 software (Figure 3). Not all receptors binding to a certain biogenic amine were composed of uniform clusters, but the appropriate receptor subgroups did. AmOct α 2R assembled in a clade that contained an α_2 -adrenergic-like octopamine receptor from *D. melanogaster* [34] and α_2 adrenergic receptors from *Platynereis dumerilii* (Pd α 2 [42]), *Saccoglossus kowalevskii* (Sk α 2 [42]), and *Priapululus caudatus* (Pc α 2 [42]). This clade was closely related to human α_2 -adrenergic receptors. In contrast, α_1 -adrenergic-like octopamine receptors including AmOct α 1R [31] were clearly set apart and formed a sister group with α_1 -adrenergic receptors (Figure 3). Both α_1 -adrenergic-like octopamine receptors and α_1 -adrenergic receptors were also closely related to the invertebrate-type dopamine receptors from *A. mellifera* (AmDOP2 [43]), *Periplaneta americana* (*P. americana*; PaDOP2 [44]), and *D. melanogaster* (DmDOP2 [45]).

The complete primary structures of the AmOct α 1R [31] and AmOct α 2R receptors were only 22.1% identical and 33.5% similar. Notably, AmOct α 2R was more closely related to α_2 -adrenergic-like octopamine receptors from the striped rice stemborer *C. suppressalis* (47.8%/55.1%), the red flour beetle *Tribolium castaneum* (46.3%/53.3%), and *D. melanogaster* (43.3%/50.8%).




Figure 2. Expression of AmOct α 2R-hemagglutinin A (HA) in flpTM cells. (a) Western blot of membrane proteins (30 μ g) from flpTM cells expressing AmOct α 2R-HA receptors were not treated (lane 1) or treated with PNGaseF (lane 2). As a control, 30 μ g of membrane proteins from nontransfected flpTM cells (lane 3) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted to a polyvinylidene difluoride (PVDF) membrane. The blot was probed with a rat anti-(hemagglutinin A) HA antibody. (b) The same blot as shown in (a) was subsequently probed with an antibody directed against the C-terminus of the cyclic nucleotide-gated (CNG) channel. The sizes of marker proteins in kDa are given on the left margin.

2.2. Expression of AmOct α 2R-HA in flpTM Cells

To unravel the intracellular signaling pathway activated by AmOct α 2R-HA and determine its pharmacological properties, flpTM cells were stably transfected with the expression construct. Independent cell lines were obtained and examined by immuno-fluorescence staining for homogeneity (Supplementary Figure S3). Additionally, AmOct α 2R-HA was examined by Western blotting (Figure 2). The anti-(hemagglutinin A) HA antibody labeled a band of ~117 kDa (Figure 2a, lanes 1 and 2), which was absent in flpTM cells (Figure 2a, lane 3). Thus, the apparent molecular weight of the receptor was significantly greater than the calculated molecular weight of AmOct α 2R-HA (81.8 kDa). Whether this difference was due to glycosylation was assessed by treating samples with and without PNGaseF separately. The mobility of the protein was not altered by PNGaseF treatment (Figure 2a, lanes 1 and 2), suggesting that AmOct α 2R-HA was not glycosylated in these cells. As an internal control, the blot was developed with an antibody directed against the cyclic nucleotide-gated (CNG) channel (Figure 2b). In this case, the treatment with PNGaseF resulted in a reduction of the apparent molecular weight of the channel protein (Figure 2b, lane 2). Therefore, the difference between the apparent and calculated molecular weights of AmOct α 2R-HA is possibly due to receptor dimerization and other post-translational modifications, e.g., phosphorylation or unusual electrophoretic mobility under denaturing conditions.




Figure 3. Phylogenetic relationships of monoaminergic receptors. Alignments were performed using Clustal W [46] by using the core amino-acid sequences of TM 1–4, TM 5, TM 6, and TM 7. The evolutionary history was inferred using the neighbor-joining method. The percentage of replicate trees, in which the associated taxa clustered together in the bootstrap test (10,000 replicates), are shown next to the branches. The tree was drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the Poisson correction method and are in the units of the number of amino acid substitutions per site. The analysis involved 76 amino acid sequences. Human rhodopsin (HsRHOD) was used to root the tree. Receptor subclasses are given on the right. The abbreviations of species are shown in alphabetical order: Am, *Apis mellifera*; Dm, *Drosophila melanogaster*; Hs, *Homo sapiens*; Pa, *Periplaneta americana*; Pc, *Priapulius caudatus*; Pd, *Platynereis dumerilii*; Sk, *Saccoglossus kowalevskii*. Protostomian species names are highlighted in red, whereas deuterostomian species names are given in blue. The accession numbers and annotations of all sequences used in the phylogenetic analysis can be found in Supplementary Table S2.

2.3. Ligand Specificity of the AmOct α 2R-HA Receptor

The α_2 -adrenergic octopamine receptors from *C. suppressalis* [33] and *D. melanogaster* [34] have been shown to attenuate [cAMP]_i upon activation. We examined whether AmOct α 2R-HA might also couple to G_i-type G proteins, thereby causing inhibition of cell-endogenous adenylyl cyclases. To examine AmOct α 2R-HA's coupling properties, cells were treated with a water-soluble forskolin analog, NKH 477, which stimulated membrane-bound adenylyl cyclases. NKH 477 led to cAMP production in both nontransfected and AmOct α 2R-HA-expressing flpTM cells. Next, we assessed the effects of the biogenic amines octopamine, tyramine, dopamine, and serotonin (10⁻⁶ M each) on NKH 477-stimulated cAMP production. The application of octopamine and tyramine led to a decrease in the Ca²⁺-dependent fluorescence signal, whereas the other amines had no effect on such signals. Cells that did not express the receptor (flpTM) showed no Ca²⁺-dependent responses after the application of biogenic amines.




Figure 4. Concentration-dependent effects of octopamine on intracellular cAMP in AmOct α 2R-HA-expressing flpTM cells. Relative fluorescence (corresponding to the amount of cAMP) is given as the percentage of the value obtained with 10 μ M NKH 477 (=100%), a water-soluble forskolin analog. All measurements were performed in the presence of 100 μ M isobutylmethylxanthine (IBMX). In the range from 10⁻⁹ M to 10⁻⁶ M, the octopamine activation of AmOct α 2R-HA led to a concentration-dependent decrease in the fluorescence signal. Conversely, an increase in the fluorescence signal was observed with octopamine concentrations of 3 \times 10⁻⁶ M and higher. Data points represent the mean \pm SD of four-fold determinations.

To further investigate AmOct α 2R-HA's properties, the concentration–response curves for octopamine and tyramine were established. Octopamine was applied in concentrations ranging from 10⁻⁹ M to 10⁻⁴ M. Unexpectedly the concentration–response curve was U-shaped (Figure 4). A decrease in fluorescence was observed with octopamine concentrations ranging from 10⁻⁹ M to 10⁻⁶ M. Considering octopamine concentrations from 10⁻⁹ M to 3 \times 10⁻⁶ M, EC₅₀ was observed with 1.17 \times 10⁻⁷ M octopamine (logEC₅₀ \pm SD = -6.932 \pm 0.1395; for the mean values of all experiments, see Table 1). The maximal reduction of cAMP synthesis was ~25% at 10⁻⁶ M octopamine. Octopamine concentrations higher than 10⁻⁶ M led to an increase in Ca²⁺-dependent fluorescence signals (Figure 4), suggesting that the parental flpTM cell line expresses receptors that could be activated by octopamine and cause either a cAMP response and/or direct Ca²⁺ responses [47]. To test this hypothesis, nontransfected flpTM cells were incubated with increasing octopamine concentrations (Figure 5). In the presence of NKH 477, octopamine concentrations of \geq 3 \times 10⁻⁷ M led to an increase in Fluo-4 fluorescence, which argued for the presence of such endogenous receptors. Although we did not address the molecular identity of these receptors, they most likely belong to the family of the adrenergic GPCRs that have been previously found in these cells [48].

Table 1. Mean values for the half-maximal stimulation (EC_{50} [M] and $\log EC_{50} \pm SD$) for octopamine and tyramine on AmOct α 2R-HA. Values were obtained from the nonlinear fitting of the data (n = the number of experiments) from concentration–response curves (GraphPad Prism 5.04).

	Octopamine ($n = 7$)	Tyramine ($n = 11$)
EC_{50} [M]	5.87×10^{-8}	1.85×10^{-6}
$\log EC_{50}$	-7.43 ± 0.24	-5.78 ± 0.17




Figure 5. Concentration-dependent effects of octopamine on relative fluorescence in nontransfected (control) flpTM cells. The concentration–response curves for octopamine were established in the absence (open circles) or presence (filled circles) of 10 μ M NKH 477. Relative fluorescence is given as the percentage of the value obtained with 10 μ M NKH 477 (=100%). All measurements were performed in the presence of 100 μ M IBMX. In both conditions, higher octopamine concentrations led to an increase in fluorescence. Data points represent the mean \pm SD of four values.




Figure 6. Concentration-response curves for agonists on intracellular cAMP level in AmOct α 2R-HA-expressing flpTM cells. Relative fluorescence (corresponding to the amount of cAMP) is given as the percentage of the value obtained with 10 μ M NKH 477 (=100%). All measurements were performed in the presence of 100 μ M IBMX. Data points represent the mean \pm SD of four values from a typical experiment.

The concentration–response curve for tyramine was sigmoid and saturated at a tyramine concentration of $\geq 3 \times 10^{-5}$ M (~17% reduction; Figure 6). The ligand concentration leading to the half-maximal activation of AmOct α 2R-HA (EC_{50}) was 1.628×10^{-6} M tyramine ($\log EC_{50} \pm SD = -5.788 \pm 0.092$; for the mean values of all experiments, see Table 1). In nontransfected flpTM cells, no change in the fluorescence signal was observed upon application of tyramine.

Accordingly, all subsequent measurements with antagonists (see below) were first carried out against a tyramine background. In conclusion, the results indicated that AmOct α 2R-HA has a clear (~30-fold) specificity for octopamine over tyramine and can be considered a functional α_2 -adrenergic-like octopamine receptor.




Figure 7. Effects of putative antagonists on tyramine-activated AmOct α 2R-HA. The concentration series of the substances were applied in the presence of 10 μ M NKH 477, 10 μ M tyramine, and 100 μ M IBMX. Ligands used were (a) phentolamine, (b) epinastine, (c) mianserin, and (d) yohimbine. Data represent the mean \pm SD of four values from a typical experiment. All determinations were independently repeated at least three times.

2.4. Pharmacological Properties of the AmOct α 2R-HA Receptor

The ability of various potential antagonists for impairing AmOct α 2R-HA activity was assessed in a similar way. Measurements were performed with increasing concentrations of antagonists AS-19, 5-carboxamidotryptamine (5-CT), 5-methoxytryptamine (5-MT), 8-Hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), epinastine, ketanserin, mianserin, phentolamine, and yohimbine on a nonsaturating tyramine background (10 μ M). In NKH 477-treated and tyramine-stimulated AmOct α 2R-HA expressing cells, the application of antagonists led to an increase in the fluorescence signal, because adenylyl cyclases were no longer inhibited by G_i-proteins. In Figure 7, the antagonistic effects of phentolamine, epinastine, mianserin, and yohimbine are displayed. Ligand concentrations that led to the half-maximal inhibition of AmOct α 2R-HA (IC₅₀) were determined from the concentration–response curves and are summarized in Table 2. Effective antagonists of tyramine-stimulated AmOct α 2R-HA were, for example, 5-CT and phentolamine with IC₅₀ values of 4.16×10^{-9} M and 5.6×10^{-9} M. The order of antagonist potency of tyramine-stimulated AmOct α 2R-HA was 5-CT \geq phentolamine > epinastine > 5-MT >

mianserin > yohimbine > ketanserin > 8-OH-DPAT (for mean values of IC₅₀, see Table 2). AS-19 did not show any effect.

Table 2. Mean values for the half-maximal inhibition (IC₅₀ [M] and logIC₅₀ ± SD) for substances with antagonistic activity on tyramine-activated AmOctα2R. Values were obtained from the nonlinear fitting of the data (*n* = number of experiments) from concentration–response curves (GraphPad Prism 5.04).

Substance	Specificity in Humans ¹	IC ₅₀ [M]	logIC ₅₀	Maximal Inhibition [%]	<i>n</i>
5-CT	agonist at 5-HT _{1A} , 5-HT _{1B} , 5-HT _{1D} , 5-HT ₅ , and 5-HT ₇ receptors	4.16 × 10 ^{−9}	−8.48 ± 0.20	10.8	3
phentolamine	nonselective α-adrenergic antagonist	5.63 × 10 ^{−9}	−8.30 ± 0.20	16.1	3
epinastine	non-sedating histamine H ₁ receptor antagonist	1.98 × 10 ^{−8}	−7.75 ± 0.29	17.31	6
5-MT	agonist at 5-HT ₁ , 5-HT ₂ , 5-HT ₄ , 5-HT ₆ , and 5-HT ₇ receptors	2.06 × 10 ^{−8}	−7.72 ± 0.20	20.3	4
mianserin	antagonist at the histamine H ₁ , 5-HT _{1D} , 5-HT _{2A} , 5-HT _{2C} , 5-HT ₃ , 5-HT ₆ , 5-HT ₇ , α ₁ -adrenergic and α ₂ -adrenergic receptors high affinity for the α ₂ -adrenergic receptor, moderate affinity for the α ₁ -adrenergic, 5-HT _{1A} , 5-HT _{1B} , 5-HT _{1D} , 5-HT _{1F} , 5-HT _{2B} , and D ₂ receptors, and weak affinity for the 5-HT _{1E} , 5-HT _{2A} , 5-HT _{5A} , 5-HT ₇ , and D ₃ receptors; behaves as an antagonist at α ₁ -adrenergic, α ₂ -adrenergic, 5-HT _{1B} , 5-HT _{1D} , 5-HT _{2A} , 5-HT _{2B} and D ₂ , and as a partial agonist at 5-HT _{1A}	2.95 × 10 ^{−8}	−7.71 ± 0.31	21.5	5
yohimbine	affinity for multiple GPCR; antagonist at 5-HT _{2A} and 5-HT _{2C} receptors; high affinity for α ₁ -adrenergic receptors and very high affinity for histamine H ₁ receptors; moderate affinity for α ₂ -adrenergic and 5-HT ₆ receptors as well as weak affinity for dopamine D ₁ and D ₂ receptors	8.14 × 10 ^{−8}	−7.12 ± 0.32	14.3	4
ketanserin	standard selective 5-HT _{1A} agonist; also has moderate affinity for 5-HT ₇ receptors	5.14 × 10 ^{−7}	−6.29 ± 0.29	17.11	3
8-OH-DPAT	agonist at the 5-HT ₇ receptor	1.09 × 10 ^{−6}	−6.15 ± 0.36	7.21	3
AS-19	agonist at the 5-HT ₇ receptor	no effect			6

¹ These data have been obtained from the websites of Tocris (<https://www.tocris.com/>) and/or Sigma-Aldrich (<https://www.sigmaaldrich.com>).

Substances, which showed antagonistic activity at AmOctα2R-HA against a tyramine background, were also tested against an octopamine background (3 × 10^{−7} M). The rank order of potency was similar to measurements performed with tyramine. The mean values for half-maximal inhibition (IC₅₀ [M] and logIC₅₀ ± SD) are summarized in Table S3.

3. Discussion

There is ongoing interest in precisely understanding the physiological and behavioral roles of octopaminergic signaling in insects [2,6,26,49–51]. An important step to meet this challenge is to determine the molecular and functional pharmacological properties of octopamine receptor subtypes. Here, we described the functional characterization of AmOctα2R, the sixth octopamine receptor subtype of the honeybee. The primary structure of AmOctα2R phylogenetically clustered with protostomian α₂-adrenergic-like octopamine receptors. Activation of AmOctα2R by the phenolamines octopamine and tyramine led to a substantial decrease of NKH 477-induced cAMP synthesis. In contrast to DmOctα2R from *D. melanogaster* [34], we did not observe any changes in [cAMP]_i in response to the indoleamine serotonin.

3.1. Gene Structure, Structural Properties of the Protein, and Phylogenetic Classification

The coding region of the *AmOctα2R* gene was dispersed over approximately 13 kb of genomic DNA on the linkage group LG15 and was interrupted by two introns. The gene was located on the same chromosome, as the *AmOctα1R* gene of which the coding region was interrupted by eight introns (Table S1, Figure S1; [31,35]). Whereas the position of intron 1 was conserved between orthologous receptors of *A. mellifera* and *D. melanogaster*, this is not the case for intron 2 (Figure S1). Since amplification

on brain cDNA resulted in only one distinct product, we found no evidence for alternative splicing of the *AmOctα2R* transcript, as has been described for transcripts of orthologous receptors of both *C. suppressalis* [33] and *D. melanogaster* [34].

Applying several *in silico* analyses confirmed that *AmOctα2R* is a member of the class A (rhodopsin-like) GPCR family. This assessment was supported by the presence of cognate amino acid residues and motifs within the TM segments in *AmOctα2R*, e.g., N₇₂₀PFIY in TM7 or the D₃₆₀RY motif at the C-terminal end of TM3.

Most class A (rhodopsin-like) GPCRs were activated by ligands docking to specific residues in the binding pocket of the receptor near the extracellular side. Functionally important amino acid residues present in α_2 -adrenergic-like octopamine receptors were well conserved in the *AmOctα2R* sequence. They were an aspartic acid residue (D₃₄₂) in TM3 and two of three closely grouped serine residues found in TM5 (S_{426,430}) (see Supplementary Figure S2). Octopamine appeared to bind via its amine group and its hydroxyl group to the aspartic acid and one of the serine residues of the receptor, respectively [52,53]. In addition, phenylalanine and/or tryptophan residues in TM6 and TM7 (see Supplementary Figure S2) might contribute to π - π interaction with delocalized electrons in octopamine or tyramine and stabilize the receptor ligand interaction.

The coupling of GPCRs to specific G proteins is brought about by amino-acid residues in close vicinity to the plasma membranes of the 2nd and 3rd intracellular loops and of the cytoplasmic C-terminus of the receptor [54–56]. Biogenic amine receptors that couple to G_i proteins and thereby inhibit adenylyl cyclase activity often possess short C termini [54]. This feature is conserved in *AmOctα2R* and in other α_2 -adrenergic-like octopamine receptors (Supplementary Figure S2; [33,34]). In addition, the receptors possess strikingly similar amino-acid sequences in the vicinity of TM5 and TM6 within their 3rd cytoplasmic loops, a region largely determining the specificity of receptor/G protein coupling [57].

Our phylogenetic analysis including all major insect biogenic amine GPCR families resulted in a well-resolved phylogram (Figure 3). Protostomian α_2 -adrenergic-like octopamine receptors seemed to be closely related to deuterostomian α_2 -adrenergic receptors, emphasizing the idea of “ligand-hopping” during evolution of aminergic GPCRs [35]. When new receptors evolved by gene duplication, they needed new ligands. Because of structural constraints, the only way to obtain “new” aminergic ligands was to repurpose already existing biogenic amines from other systems. The frequent ligand exchanges during evolution of aminergic GPCRs strongly contrasted the situation observed for neuropeptide and protein hormone GPCRs, where generally co-evolution between receptors and their ligands takes place [35,58,59].

The sister group of both α_2 -adrenergic-like octopamine and α_2 -adrenergic receptors constituted type 1 tyramine receptors which also couple to G_i proteins (Figure 3; [33,34]). A slightly different assignment of the α_2 -adrenergic-like octopamine receptor family has been described in an independent study. Here, the phylogenetic trees were calculated with RAxML using the CIPRES Science Gateway [42]. The α_2 -adrenergic-like octopamine receptors assembled at the basal branches of the dendrogram forming the sister group of all other tyramine-, octopamine-, and adrenergic receptors. The different results may originate from the strategies applied in creating the datasets used for calculating the phylograms. Based on our results, we suggest including all major receptor families to unravel the evolutionary relationship of biogenic amine receptors.

3.2. Posttranslational Modification of *AmOctα2R*

Posttranslational modifications in intracellular loops of *AmOctα2R*, like phosphorylation, may also affect the signaling properties of the protein. It has been recently shown that phosphorylation of a single residue in the third intracellular loop of an octopamine receptor from *D. melanogaster* (DmOctαR1B; [60,61] is sufficient to explain the receptor’s oscillatory Ca²⁺ signaling behavior [62]. Whether transient changes in the surface charge of *AmOctα2R* also lead to oscillatory phases of adenylyl cyclase inhibition remains to be addressed. Cysteine residues in the C-terminus of different biogenic

amine receptors were found to undergo posttranslational palmitoylation [63]. This modification generates a fourth intracellular loop that also participates in receptor-G protein binding [59]. Since a cysteine is missing in the C-terminus of AmOct α 2R, the fourth intracellular loop does not exist in this GPCR.

3.3. Pharmacological Properties of the AmOct α 2R Protein

The AmOct α 2R receptor was functionally expressed in flpTM cells. The coupling of AmOct α 2R to intracellular signaling cascades was examined via cell-endogenous G proteins. AmOct α 2R, like other α_2 -adrenergic-like octopamine receptors from insects [33,34] and mammalian α_2 -adrenergic receptors (for a review, see [64]), was negatively coupled to the enzyme adenylyl cyclase via G_i proteins and thus resulted in a decrease in [cAMP]_i. With a mean EC₅₀ of 58.7 nM, activation of AmOct α 2R was much more sensitive to octopamine than to tyramine (mean EC₅₀ = 1.85 μ M; Table 1). These data agree well with those described for orthologous receptors [33,34]. Interestingly, besides cAMP signaling, the addition of octopamine, tyramine (and dopamine) to CsOct α 2R-expressing HEK 293 cells also resulted in concentration-dependent increases in [Ca²⁺]_i. This has not been found for DmOct α 2R- [34] or AmOct α 2R-expressing cells (this study). However, apart from obvious similarities in the pharmacological properties, there were also significant differences between DmOct α 2R and AmOct α 2R. Whereas DmOct α 2R was activated by serotonin in a dose-dependent manner (EC₅₀ = 1.04 μ M; [34]), serotonin failed to activate AmOct α 2R.

The inhibition of AmOct α 2R-HA-mediated attenuation of [cAMP]_i in the cell line was examined with various synthetic antagonists. In addition to phentolamine (IC₅₀ = 5.6 nM/8.21 nM) which is a nonselective α -adrenergic antagonist (for a review, see [65]), the action of tyramine and octopamine on AmOct α 2R could also be blocked by 5-CT (IC₅₀ = 4.16 nM/0.27 nM) with even slightly higher potency. The substance 5-CT is primarily known as an agonist at 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1D}, 5-HT₅, and 5-HT₇ receptors in mammals [66] and in insects [11,67,68]. Additional serotonergic ligands (e.g., the agonist 5-MT (IC₅₀ = 20.6 nM/836 nM) and the antagonist mianserin (IC₅₀ = 29.5 nM/21.5 nM)) were also potent blockers of the action of tyramine and octopamine on AmOct α 2R. Mianserin is known for some time as a potent antagonist at octopamine receptors [69,70] and, more recently, was found to be an antagonist of the AmTAR2 receptor of the honeybee [30] and the PeaTAR1B receptor of the American cockroach, *P. americana* [71].

Overall, our results support the notion that octopamine signaling in insects is highly complex. It is noteworthy that octopamine receptors characterized so far have been shown to preferentially couple to G_s proteins to activate adenylyl cyclases and to G_q-proteins, which induce intracellular Ca²⁺ mobilization (for reviews, see [2,4,72]). However, α_2 -adrenergic-like octopamine receptors have been found to inhibit adenylyl cyclase activity ([33,34] and this study), a property reminiscent of the phylogenetically related mammalian α_2 -adrenergic receptors (for a review, see [64]) and insect type 1 tyramine receptors (e.g., [27,28,47,71,73–75]). Whether the signaling properties of a given receptor in a cell line illustrates its typical behavior in a natural background would require experimental testing in native cell or tissue samples. To the best of our knowledge, only stimulatory actions of octopamine on adenylyl cyclase activity have been reported so far for native tissues of the honeybee [27,72] and other insects [76–80] as well as for insect cells lines [81–83]. We speculate that the inhibitory effects of α_2 -adrenergic-like octopamine receptors on adenylyl cyclase activity are masked by the effects of the more prominent α_1 -adrenergic-like and β -adrenergic-like octopamine receptors. To test this hypothesis, native cells, tissue, or organs should be identified that express AmOct α 2R as the only phenolamine receptor. An alternative could be the use of well-characterized pharmacological tools that permit the selective and efficient activation or inhibition of one or the other receptor in preparations expressing more than one phenolamine receptor. We have successfully used such a strategy to disentangle the signaling pathways of 5-HT₂ and 5-HT₇ serotonin receptors, which are co-expressed in blowfly (*Calliphora vicina*) salivary glands [84]. In any case, the characterization of the signaling properties of a

sixth member of the octopamine receptor family presented here for the honeybee should facilitate future *in vivo* pharmacological studies coupled with behavioral testing in this eusocial model organism.

4. Materials and Methods

4.1. Amplification of the Honeybee α_2 -Adrenergic-Like Octopamine Receptor (*AmOct α 2R*) cDNA and Construction of *pcAmOct α 2R-HA* Expression Vector

Total RNA was extracted from 10 brains of honeybee foragers using the RNeasy Plus Micro Kit (Qiagen, Hilden, Germany). Synthesis of cDNA was carried out with M-MLV Reverse Transcriptase (Invitrogen/ThermoFisher Scientific, Dreieich, Germany). For the amplification of the entire coding region of *AmOct α 2R*, specific primers were designed based on available sequence information ([35]; GenBank accession number XM_001122075): sense primer 5'-CGAGGAATTCCACCATGCCGCTCC TCGGCACC-3'; antisense primer 5'-GACGTCTAGATTATGCATAGTCGGGGACGTCATAGGGA TATTTGAAGAGTATCCTGCGG-3' (eurofins, Ebersberg, Germany). Primers were designed to enable ligation into pcDNA3.1(+) vector (Invitrogen/ThermoFisher Scientific, Dreieich, Germany) and heterologous expression of *AmOct α 2R* in eukaryotic cells. In the sense primer, an EcoRI restriction site and a Kozak consensus motif (CCACC; [85]) were inserted in front of the translational start codon. In the antisense primer, the receptor-encoding sequence was extended in a frame with a sequence encoding the hemagglutinin A (HA) tag to allow monitoring of receptor protein expression using specific anti-HA antibodies (Roche/Sigma-Aldrich/Merck, Darmstadt, Germany). In addition, an XbaI recognition sequence was introduced immediately after the stop codon (TAA). PCR was performed using the following protocol: 95 °C for 10 min, 35 cycles at 95 °C for 30 s, 65 °C for 30 s, and 72 °C for 150 s and a final extension at 72 °C for 5 min. The PCR product was separated by agarose gel electrophoresis. The fragment was excised from the gel, cleaned using a PCR clean-up and gel extraction kit (Macherey-Nagel, Düren, Germany), double-restricted with EcoRI and XbaI and cloned into the pcDNA3.1(+) vector. The expression construct (*pcAmOct α 2R-HA*) was verified by sequencing on both strands (eurofins).

4.2. Multiple Sequence Alignment and Phylogenetic Analysis

For phylogenetic analysis, we included amino acid sequences of biogenic amine receptors of various protostomian and deuterostomian species. Sequences were obtained from NCBI databases (NCBI, Bethesda, MD, USA). Multiple amino acid sequence alignment was consequently trimmed to regions encoding TM 1–4, TM 5, TM 6, and TM 7 using ClustalW. Afterwards, evolutionary analyses were conducted in MEGA7 [86]. The evolutionary history was inferred using the neighbor-joining method [87] with 10,000-fold bootstrap resampling. The human rhodopsin sequence formed the outgroup.

The sequence identity and similarity of α_2 -adrenergic-like octopamine receptors between *A. mellifera*, *B. mori*, and *D. melanogaster* were determined by using BioEdit v. 7.0.5.3 [88] after pairwise alignment.

4.3. Functional Expression of the *AmOct α 2R-HA* Receptor

For *AmOct α 2R-HA* expression and pharmacological analysis, we used a human embryonic kidney (HEK293; flpIn cells; Invitrogen/ThermoFisher Scientific; #750-07)-based cell line that was transfected with a gene encoding a variant of the A2-subunit of the olfactory CNG ion channel [89] (flpTM cells), provided by Sibion biosciences, Jülich, Germany. These flpTM cells were transfected with 3 μ g, 8 μ g, or 12 μ g of the *pcAmOct α 2R-HA* construct by a modified calcium phosphate method [90] following a previously established protocol [48]. Transfected cells were selected in the presence of the antibiotics G418 (1 mg/mL) and hygromycin (100 μ g/mL). Expression of *AmOct α 2R-HA* was monitored by Western blotting and immunocytochemistry using anti-HA antibodies (Roche/Sigma-Aldrich/Merck).

4.4. Functional Analysis of the AmOct α 2R-HA Receptor

A stably transfected cell line was used to examine AmOct α 2R-HA receptor activity by Ca²⁺ imaging. Control measurements were performed in the parental (flpTM) cell line. Changes in [cAMP]_i were registered indirectly via co-expressed CNG channels that were opened by cAMP and cause an influx of extracellular Ca²⁺ [30,32,48]. Changes in [Ca²⁺]_i were monitored with the Ca²⁺-sensitive fluorescent dye Fluo-4. Cells were grown in 96-well dishes to a density of approximately 2 × 10⁴ cells per well and were loaded at room temperature with Fluo-4 AM as described previously [32]. After 90 min, the loading solution was substituted with a dye-free extracellular solution (ECS; 120 mM NaCl, 5 mM KCl, 2 mM MgCl₂, 2 mM CaCl₂, 10 mM HEPES, and 10 mM glucose, pH 7.4 (NaOH)) containing 100 μM IBMX. The plate was transferred into a fluorescence reader (FLUOstar Omega, BMG Labtech, Ortenberg, Germany) to monitor Fluo-4 fluorescence. The excitation wavelength was 485 nm. Fluorescence emission was detected at 520 nm. Concentration series of various biogenic amines and synthetic receptor ligands were added, once Fluo-4 fluorescence intensity reached a stable value in each well. The changes in Fluo-4 fluorescence were recorded automatically. Concentration–response curves were established from at least three independent experiments with quadruplicate measurements. Data were analyzed and displayed using Prism 5.04 software (GraphPad, San Diego, CA, USA).

4.5. Western Blot Analysis

Membrane proteins from AmOct α 2R-HA-expressing cells and non-transfected flpTM cells were prepared as described previously [32]. Briefly, cells were lysed in buffer A (10 mM NaCl, 25 mM HEPES (pH 7.5), 2 mM EDTA, and a mammalian protease inhibitor cocktail diluted at 1:500 (mPIC; Sigma-Aldrich/Merck, Darmstadt, Germany)). After centrifugation, membrane proteins were solubilized from the pellet with buffer B (100 mM NaCl, 25 mM HEPES pH 7.5, mPIC protease inhibitor (dilution, 1:500) and 1% (*w/v*) (3-((3-cholamidopropyl)-dimethylammonio)-1-propanesulfonate, (CHAPS)). Proteins (30 μg per lane) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; 10% gel) and transferred onto a polyvinylidene fluoride membrane (PVDF, Merck/Millipore, Darmstadt, Germany). Nonspecific binding sites were blocked by incubation for 30 min in 5% (*w/v*) dry milk in phosphate buffered saline (PBS; 130 mM NaCl, 7 mM Na₂HPO₄, and 3 mM NaH₂PO₄; pH: 7.4). The membrane was incubated with primary antibodies (anti-HA; dilution, 1:1000; Roche/Sigma-Aldrich/Merck) in PBS containing 0.02% (*v/v*) Tween-20 (PBT) overnight at 4 °C. After rinsing the membrane three times with PBT for 15 min each, secondary antibodies conjugated to horseradish peroxidase (donkey anti-rat-HRP; dilution, 1:5000 (Sigma-Aldrich/Merck, Darmstadt, Germany)) in PBT containing 0.5% (*w/v*) dry milk were added for 1 h at room temperature. After rinsing the membrane three times with PBT for 15 min each and two times with PBS for 5 min each, signals were visualized with an enhanced chemiluminescence detection system (Western Bright™-Kit; Advansta; San Jose, CA, USA) on Hyperfilm™ ECL (GE Healthcare/Merck, Darmstadt, Germany).

Supplementary Materials: Supplementary materials can be found at <http://www.mdpi.com/1422-0067/21/24/9334/s1>.

Author Contributions: Conceptualization, W.B. and A.B.; validation, W.B. and A.B.; formal analysis, W.B., J.A.W., and S.B.; investigation, W.B., J.A.W., and S.B.; writing of the original draft preparation, W.B. and A.B.; writing of review and editing, W.B., J.A.W., S.B., and A.B.; supervision, W.B. and A.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: The authors would like to thank Paul A. Stevenson (University of Leipzig) for the constructive criticism of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

5-CT	5-carboxamidotryptamine
5-MT	5-methoxytryptamine
5-HT	5-hydroxytryptamine, serotonin
8-OH-DPAT	8-Hydroxy-2-(dipropylamino)tetralin
GPCR	G protein-coupled receptor
HA	hemagglutinin A
IBMX	3-isobutyl-1-methylxanthine
NKH477	water-soluble forskolin analog
RFU	relative fluorescence unit
TM	transmembrane

References

- Blenau, W.; Baumann, A. Aminergic signal transduction in invertebrates: Focus on tyramine and octopamine receptors. *Recent Res. Dev. Neurochem.* **2003**, *6*, 225–240.
- Blenau, W.; Baumann, A. Octopaminergic and tyraminergeric signaling in the honeybee (*Apis mellifera*) brain: Behavioral, pharmacological, and molecular aspects. In *Trace Amines and Neurological Disorders*, 1st ed.; Farooqui, A., Ed.; Academic Press: Oxford, UK, 2016; pp. 203–220.
- Lange, A.B. Tyramine: From octopamine precursor to neuroactive chemical in insects. *Gen. Comp. Endocrinol.* **2009**, *162*, 18–26. [[CrossRef](#)] [[PubMed](#)]
- Verlinden, H.; Vleugels, R.; Marchal, E.; Badisco, L.; Pflüger, H.J.; Blenau, W.; Vanden Broeck, J. The role of octopamine in locusts and other arthropods. *J. Insect Physiol.* **2010**, *56*, 854–867. [[CrossRef](#)] [[PubMed](#)]
- Ohta, H.; Ozoe, Y. Molecular signalling, pharmacology, and physiology of octopamine and tyramine receptors as potential insect pest control targets. *Adv. Insect Physiol.* **2014**, *46*, 73–166.
- Roeder, T. The control of metabolic traits by octopamine and tyramine in invertebrates. *J. Exp. Biol.* **2020**, *223*, jeb194282. [[CrossRef](#)]
- Hammer, M. An identified neuron mediates the unconditioned stimulus in associative olfactory learning in honeybees. *Nature* **1993**, *366*, 59–63. [[CrossRef](#)]
- Farooqui, T.; Robinson, K.; Vaessin, H.; Smith, B.H. Modulation of early olfactory processing by an octopaminergic reinforcement pathway in the honeybee. *J. Neurosci.* **2003**, *23*, 5370–5380. [[CrossRef](#)]
- Giurfa, M. Associative learning: The instructive function of biogenic amines. *Curr. Biol.* **2006**, *16*, R892–R895. [[CrossRef](#)]
- Vergoz, V.; Roussel, E.; Sandoz, J.C.; Giurfa, M. Aversive learning in honeybees revealed by the olfactory conditioning of the sting extension reflex. *PLoS ONE* **2007**, *2*, e288. [[CrossRef](#)]
- Thamm, M.; Balfanz, S.; Scheiner, R.; Baumann, A.; Blenau, W. Characterization of the 5-HT_{1A} receptor of the honeybee (*Apis mellifera*) and involvement of serotonin in phototactic behavior. *Cell. Mol. Life Sci.* **2010**, *67*, 2467–2479. [[CrossRef](#)]
- Mancini, N.; Giurfa, M.; Sandoz, J.C.; Avarguès-Weber, A. Aminergic neuromodulation of associative visual learning in harnessed honey bees. *Neurobiol. Learn. Mem.* **2018**, *155*, 556–567. [[CrossRef](#)] [[PubMed](#)]
- Schulz, D.J.; Robinson, G.E. Octopamine influences division of labor in honey bee colonies. *J. Comp. Physiol. A* **2001**, *187*, 53–61. [[CrossRef](#)]
- Lehman, H.K.; Schulz, D.J.; Barron, A.B.; Wraight, L.; Hardison, C.; Whitney, S.; Takeuchi, H.; Paul, R.K.; Robinson, G.E. Division of labor in the honey bee (*Apis mellifera*): The role of tyramine β -hydroxylase. *J. Exp. Biol.* **2006**, *209*, 2774–2784. [[CrossRef](#)] [[PubMed](#)]
- Scheiner, R.; Baumann, A.; Blenau, W. Aminergic control and modulation of honeybee behaviour. *Curr. Neuropharmacol.* **2006**, *4*, 259–276. [[CrossRef](#)] [[PubMed](#)]
- Braun, G.; Bicker, G. Habituation of an appetitive reflex in the honeybee. *J. Neurophysiol.* **1992**, *67*, 588–598. [[CrossRef](#)] [[PubMed](#)]
- Scheiner, R.; Plüchhahn, S.; Oney, B.; Blenau, W.; Erber, J. Behavioural pharmacology of octopamine, tyramine and dopamine in honey bees. *Behav. Brain Res.* **2002**, *136*, 545–553. [[CrossRef](#)]
- Cook, C.N.; Brent, C.S.; Breed, M.D. Octopamine and tyramine modulate the thermoregulatory fanning response in honey bees (*Apis mellifera*). *J. Exp. Biol.* **2017**, *220*, 1925–1930. [[CrossRef](#)]

19. Fussnecker, B.L.; Smith, B.H.; Mustard, J.A. Octopamine and tyramine influence the behavioral profile of locomotor activity in the honey bee (*Apis mellifera*). *J. Insect Physiol.* **2006**, *52*, 1083–1092. [[CrossRef](#)]
20. Scheiner, R.; Toteva, A.; Reim, T.; Søvik, E.; Barron, A.B. Differences in the phototaxis of pollen and nectar foraging honey bees are related to their octopamine brain titers. *Front. Physiol.* **2014**, *5*, 116. [[CrossRef](#)]
21. Kutsukake, M.; Komatsu, A.; Yamamoto, D.; Ishiwa-Chigusa, S. A tyramine receptor gene mutation causes a defective olfactory behavior in *Drosophila melanogaster*. *Gene* **2000**, *245*, 31–42. [[CrossRef](#)]
22. Saraswati, S.; Fox, L.E.; Soll, D.R.; Wu, C.F. Tyramine and octopamine have opposite effects on the locomotion of *Drosophila* larvae. *J. Neurobiol.* **2004**, *58*, 425–441. [[CrossRef](#)] [[PubMed](#)]
23. Ormerod, K.G.; Hadden, J.K.; Deady, L.D.; Mercier, A.J.; Krans, J.L. Action of octopamine and tyramine on muscles of *Drosophila melanogaster* larvae. *J. Neurophysiol.* **2013**, *110*, 1984–1996. [[CrossRef](#)] [[PubMed](#)]
24. Selcho, M.; Pauls, D.; el Jundi, B.; Stocker, R.F.; Thum, A.S. The role of octopamine and tyramine in *Drosophila* larval locomotion. *J. Comp. Neurol.* **2012**, *520*, 3764–3785. [[CrossRef](#)] [[PubMed](#)]
25. Damrau, C.; Toshima, N.; Tanimura, T.; Brembs, B.; Colomb, J. Octopamine and tyramine contribute separately to the counter-regulatory response to sugar deficit in *Drosophila*. *Front. Syst. Neurosci.* **2018**, *11*, 100. [[CrossRef](#)] [[PubMed](#)]
26. Schützler, N.; Girwert, C.; Hügli, I.; Mohana, G.; Roignant, J.Y.; Ryglewski, S.; Duch, C. Tyramine action on motoneuron excitability and adaptable tyramine/octopamine ratios adjust *Drosophila* locomotion to nutritional state. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 3805–3810. [[CrossRef](#)]
27. Blenau, W.; Balfanz, S.; Baumann, A. Amtyr1: Characterization of a gene from honeybee (*Apis mellifera*) brain encoding a functional tyramine receptor. *J. Neurochem.* **2000**, *74*, 900–908. [[CrossRef](#)] [[PubMed](#)]
28. Mustard, J.A.; Kurshan, P.T.; Hamilton, I.S.; Blenau, W.; Mercer, A.R. Developmental expression of a tyramine receptor gene in the brain of the honey bee, *Apis mellifera*. *J. Comp. Neurol.* **2005**, *483*, 66–75. [[CrossRef](#)]
29. Beggs, K.T.; Tyndall, J.D.A.; Mercer, A.R. Honey bee dopamine and octopamine receptors linked to intracellular calcium signaling have a close phylogenetic and pharmacological relationship. *PLoS ONE* **2011**, *6*, e26809. [[CrossRef](#)]
30. Reim, T.; Balfanz, S.; Baumann, A.; Blenau, W.; Thamm, M.; Scheiner, R. AmTAR2: Functional characterization of a honeybee tyramine receptor stimulating adenylyl cyclase activity. *Insect Biochem. Mol. Biol.* **2017**, *80*, 91–100. [[CrossRef](#)]
31. Grohmann, L.; Blenau, W.; Erber, J.; Ebert, P.R.; Strünker, T.; Baumann, A. Molecular and functional characterization of an octopamine receptor from honeybee (*Apis mellifera*) brain. *J. Neurochem.* **2003**, *86*, 725–735. [[CrossRef](#)]
32. Balfanz, S.; Jordan, N.; Langenstück, T.; Breuer, J.; Bergmeier, V.; Baumann, A. Molecular, pharmacological, and signaling properties of octopamine receptors from honeybee (*Apis mellifera*) brain. *J. Neurochem.* **2014**, *129*, 284–296. [[CrossRef](#)] [[PubMed](#)]
33. Wu, S.F.; Xu, G.; Qi, Y.X.; Xia, R.Y.; Huang, J.; Ye, G.Y. Two splicing variants of a novel family of octopamine receptors with different signaling properties. *J. Neurochem.* **2014**, *129*, 37–47. [[CrossRef](#)] [[PubMed](#)]
34. Qi, Y.X.; Xu, G.; Gu, G.X.; Mao, F.; Ye, G.Y.; Liu, W.; Huang, J. A new *Drosophila* octopamine receptor responds to serotonin. *Insect Biochem. Mol. Biol.* **2017**, *90*, 61–70. [[CrossRef](#)] [[PubMed](#)]
35. Hauser, F.; Cazzamali, G.; Williamson, M.; Blenau, W.; Gimmelikhuijzen, C.J. A review of neurohormone GPCRs present in the fruitfly *Drosophila melanogaster* and the honey bee *Apis mellifera*. *Prog. Neurobiol.* **2006**, *80*, 1–19. [[CrossRef](#)]
36. Kyte, J.; Doolittle, R.F. A simple method for displaying the hydropathic character of a protein. *J. Mol. Biol.* **1982**, *157*, 105–132. [[CrossRef](#)]
37. Krogh, A.; Larsson, B.; von Heijne, G.; Sonnhammer, E.L. Predicting transmembrane protein topology with a hidden Markov model: Application to complete genomes. *J. Mol. Biol.* **2001**, *305*, 567–580. [[CrossRef](#)]
38. Kelley, L.A.; Mezulis, S.; Yates, C.M.; Wass, M.N.; Sternberg, M.J. The phyre2 web portal for protein modeling, prediction and analysis. *Nat. Protoc.* **2015**, *10*, 845–858. [[CrossRef](#)]
39. Kroeze, W.K.; Sheffler, D.J.; Roth, B.L. G-protein-coupled receptors at a glance. *J. Cell Sci.* **2003**, *116*, 4867–4869. [[CrossRef](#)]
40. Ballesteros, J.A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. *Methods Neurosci.* **1995**, *25*, 366–428.

41. Eilers, M.; Hornak, V.; Smith, S.O.; Konopka, J.B. Comparison of class a and dg protein-coupled receptors: Common features in structure and activation. *Biochemistry* **2005**, *44*, 8959–8975. [[CrossRef](#)]
42. Bauknecht, P.; Jékely, G. Ancient coexistence of norepinephrine, tyramine, and octopamine signaling in bilaterians. *BMC Biol.* **2017**, *15*, 6. [[CrossRef](#)] [[PubMed](#)]
43. Mustard, J.A.; Blenau, W.; Hamilton, I.S.; Ward, V.K.; Ebert, P.R.; Mercer, A.R. Analysis of two D1-like dopamine receptors from the honey bee *Apis mellifera* reveals agonist-independent activity. *Brain Res. Mol. Brain Res.* **2003**, *113*, 67–77. [[CrossRef](#)]
44. Troppmann, B.; Balfanz, S.; Krach, C.; Baumann, A.; Blenau, W. Characterization of an invertebrate-type dopamine receptor of the American cockroach, *Periplaneta americana*. *Int. J. Mol. Sci.* **2014**, *15*, 629–653. [[CrossRef](#)] [[PubMed](#)]
45. Feng, G.; Hannan, F.; Reale, V.; Hon, Y.Y.; Kousky, C.T.; Evans, P.D.; Hall, L.M. Cloning and functional characterization of a novel dopamine receptor from *Drosophila melanogaster*. *J. Neurosci.* **1996**, *16*, 3925–3933. [[CrossRef](#)] [[PubMed](#)]
46. Thompson, J.D.; Higgins, D.G.; and Gibson, T.J. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res.* **1994**, *22*, 4673–4680. [[CrossRef](#)] [[PubMed](#)]
47. Rotte, C.; Krach, C.; Balfanz, S.; Baumann, A.; Walz, B.; Blenau, W. Molecular characterization and localization of the first tyramine receptor of the American cockroach (*Periplaneta americana*). *Neuroscience* **2009**, *162*, 1120–1133. [[CrossRef](#)] [[PubMed](#)]
48. Wachten, S.; Schlenstedt, J.; Gauss, R.; Baumann, A. Molecular identification and functional characterization of an adenylyl cyclase from the honeybee. *J. Neurochem.* **2006**, *96*, 1580–1590. [[CrossRef](#)]
49. Li, Y.; Hoffmann, J.; Li, Y.; Stephano, F.; Bruchhaus, I.; Fink, C.; Roeder, T. Octopamine controls starvation resistance, life span and metabolic traits in *Drosophila*. *Sci. Rep.* **2016**, *6*, 35359. [[CrossRef](#)]
50. Sujkowski, A.; Ramesh, D.; Brockmann, A.; Wessells, R. Octopamine drives endurance exercise adaptations in *Drosophila*. *Cell Rep.* **2017**, *21*, 1809–1823. [[CrossRef](#)]
51. Selcho, M.; Pauls, D. Linking physiological processes and feeding behaviors by octopamine. *Curr. Opin. Insect Sci.* **2019**, *36*, 125–130. [[CrossRef](#)]
52. Ohta, H.; Utsumi, T.; Ozoe, Y. Amino acid residues involved in interaction with tyramine in the *Bombyx mori* tyramine receptor. *Insect Mol. Biol.* **2004**, *13*, 531–538. [[CrossRef](#)] [[PubMed](#)]
53. Congreve, M.; Langmead, C.; Marshall, F.H. The use of GPCR structures in drug design. *Adv. Pharmacol.* **2011**, *62*, 1–36. [[PubMed](#)]
54. Probst, W.C.; Snyder, L.A.; Schuster, D.I.; Brosius, J.; Sealfon, S.C. Sequence alignment of the G-protein coupled receptor superfamily. *DNA Cell Biol.* **1992**, *11*, 1–20. [[CrossRef](#)] [[PubMed](#)]
55. Kobilka, B.K. G protein coupled receptor structure and activation. *Biochim. Biophys. Acta* **2007**, *1768*, 794–807. [[CrossRef](#)]
56. Karageorgos, V.; Venihaki, M.; Sakellaris, S.; Pardalos, M.; Kontakis, G.; Matsoukas, M.T.; Gravanis, A.; Margioris, A.; Liapakis, G. Current understanding of the structure and function of family B GPCRs to design novel drugs. *Hormones* **2018**, *17*, 45–59. [[CrossRef](#)]
57. Bockaert, J.; Pin, J.P. Molecular tinkering of G protein-coupled receptors: An evolutionary success. *EMBO J.* **1999**, *18*, 1723–1729. [[CrossRef](#)] [[PubMed](#)]
58. Jékely, G. Global view of the evolution and diversity of metazoan neuropeptide signaling. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 8702–8707. [[CrossRef](#)]
59. Elphick, M.R.; Mirabeau, O.; Larhammar, D. Evolution of neuropeptide signalling systems. *J. Exp. Biol.* **2018**, *221*, jeb151092. [[CrossRef](#)] [[PubMed](#)]
60. Balfanz, S.; Strünker, T.; Frings, S.; Baumann, A. A family of octopamine receptors that specifically induce cyclic AMP production or Ca²⁺ release in *Drosophila melanogaster*. *J. Neurochem.* **2005**, *93*, 440–451. [[CrossRef](#)] [[PubMed](#)]
61. Han, K.A.; Millar, N.S.; Davis, R.L. A novel octopamine receptor with preferential expression in *Drosophila* mushroom bodies. *J. Neurosci.* **1998**, *18*, 3650–3658. [[CrossRef](#)]
62. Hoff, M.; Balfanz, S.; Ehling, P.; Gensch, T.; Baumann, A. A single amino acid residue controls Ca²⁺ signaling by an octopamine receptor from *Drosophila melanogaster*. *FASEB J.* **2011**, *25*, 2484–2491. [[CrossRef](#)] [[PubMed](#)]

63. O'Dowd, B.F.; Hnatowich, M.; Caron, M.G.; Lefkowitz, R.J.; Bouvier, M. Palmitoylation of the human β_2 -adrenergic receptor. Mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor. *J. Biol. Chem.* **1989**, *264*, 7564–7569. [[PubMed](#)]
64. Docherty, J.R. Subtypes of functional α_1 - and α_2 -adrenoceptors. *Eur. J. Pharmacol.* **1998**, *361*, 1–15. [[CrossRef](#)]
65. Goldstein, I. Oral phentolamine: An alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction. *Int. J. Impot. Res.* **2000**, *12*, S75–S80. [[CrossRef](#)] [[PubMed](#)]
66. Yamada, J.; Sugimoto, Y.; Noma, T.; Yoshikawa, T. Effects of the non-selective 5-HT receptor agonist, 5-carboxamidotryptamine, on plasma glucose levels in rats. *Eur. J. Pharmacol.* **1998**, *359*, 81–86. [[CrossRef](#)]
67. Schlenstedt, J.; Balfanz, S.; Baumann, A.; Blenau, W. Am5-HT₇: Molecular and pharmacological characterization of the first serotonin receptor of the honeybee (*Apis mellifera*). *J. Neurochem.* **2006**, *98*, 1985–1998. [[CrossRef](#)]
68. Troppmann, B.; Balfanz, S.; Baumann, A.; Blenau, W. Inverse agonist and neutral antagonist actions of synthetic compounds at an insect 5-HT₁ receptor. *Br. J. Pharmacol.* **2010**, *159*, 1450–1562. [[CrossRef](#)]
69. Minhas, N.; Gole, J.W.D.; Orr, G.L.; Downer, R.G.H. Pharmacology of [³H]mianserin binding in the nerve cord of the American cockroach, *Periplaneta americana*. *Arch. Insect Biochem. Physiol.* **1987**, *6*, 191–201. [[CrossRef](#)]
70. Roeder, T. High-affinity antagonists of the locust neuronal octopamine receptor. *Eur. J. Pharmacol.* **1990**, *191*, 221–224. [[CrossRef](#)]
71. Blenau, W.; Balfanz, S.; Baumann, A. PeaTAR1B: Characterization of a second type 1 tyramine receptor of the American cockroach, *Periplaneta americana*. *Int. J. Mol. Sci.* **2017**, *18*, 2279. [[CrossRef](#)]
72. Evans, P.D.; Maqueira, B. Insect octopamine receptors: A new classification scheme based on studies of cloned *Drosophila* G-protein coupled receptors. *Invert. Neurosci.* **2005**, *5*, 111–118. [[CrossRef](#)] [[PubMed](#)]
73. Saudou, F.; Amlaiky, N.; Plassat, J.L.; Borrelli, E.; Hen, R. Cloning and characterization of a *Drosophila* tyramine receptor. *EMBO J.* **1990**, *9*, 3611–3617. [[CrossRef](#)] [[PubMed](#)]
74. Vanden Broeck, J.; Vulsteke, V.; Huybrechts, R.; De Loof, A. Characterization of a cloned locust tyramine receptor cDNA by functional expression in permanently transformed *Drosophila* S2 cells. *J. Neurochem.* **1995**, *64*, 2387–2395. [[CrossRef](#)] [[PubMed](#)]
75. Ohta, H.; Utsumi, T.; Ozoe, Y. B96Bom encodes a *Bombyx mori* tyramine receptor negatively coupled to adenylyl cyclase. *Insect Mol. Biol.* **2003**, *12*, 217–223. [[CrossRef](#)]
76. Hildebrandt, H.; Müller, U. Octopamine mediates rapid stimulation of protein kinase A in the antennal lobe of honeybees. *J. Neurobiol.* **1995**, *27*, 44–50. [[CrossRef](#)] [[PubMed](#)]
77. Uzzan, A.; Dudai, Y. Aminergic receptors in *Drosophila melanogaster*: Responsiveness of adenylyl cyclase to putative neurotransmitters. *J. Neurochem.* **1982**, *38*, 1542–1550. [[CrossRef](#)]
78. Gole, J.W.; Orr, G.L.; Downer, R.G.H. Interaction of formamidines with octopamine-sensitive adenylyl cyclase receptor in the nerve cord of *Periplaneta americana* L. *Life Sci.* **1983**, *32*, 2939–2947. [[CrossRef](#)]
79. Orr, G.L.; Gole, J.W.D.; Downer, R.G.H. Characterisation of an octopamine-sensitive adenylyl cyclase in haemocyte membrane fragments of the American cockroach, *Periplaneta americana* L. *Insect Biochem.* **1985**, *15*, 695–701. [[CrossRef](#)]
80. Aoyama, M.; Nakane, T.; Ono, T.; Khan, M.A.; Ohta, H.; Ozoe, Y. Substituent-dependent, positive and negative modulation of *Bombyx mori* adenylyl cyclase by synthetic octopamine/tyramine analogues. *Arch. Insect Biochem. Physiol.* **2001**, *47*, 1–7. [[CrossRef](#)]
81. Orr, N.; Orr, G.L.; Hollingworth, R.M. The Sf9 cell line as a model for studying insect octopamine-receptors. *Insect Biochem. Mol. Biol.* **1992**, *22*, 591–597. [[CrossRef](#)]
82. Van Poyer, W.; Torfs, H.; Poels, J.; Swinnen, E.; De Loof, A.; Akerman, K.; Vanden Broeck, J. Phenolamine-dependent adenylyl cyclase activation in *Drosophila* Schneider 2 cells. *Insect Biochem. Mol. Biol.* **2001**, *31*, 333–338. [[CrossRef](#)]
83. Näsman, J.; Kukkonen, J.P.; Akerman, K.E. Dual signalling by different octopamine receptors converges on adenylyl cyclase in Sf9 cells. *Insect Biochem. Mol. Biol.* **2002**, *32*, 285–293. [[CrossRef](#)]
84. Röser, C.; Jordan, N.; Balfanz, S.; Baumann, A.; Walz, B.; Baumann, O.; Blenau, W. Molecular and pharmacological characterization of serotonin 5-HT_{2α} and 5-HT₇ receptors in the salivary glands of the blowfly *Calliphora vicina*. *PLoS ONE* **2012**, *7*, e49459. [[CrossRef](#)] [[PubMed](#)]
85. Kozak, M. Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. *Nucleic Acids Res.* **1984**, *12*, 857–872. [[CrossRef](#)]

86. Kumar, S.; Stecher, G.; Tamura, K. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. *Mol. Bio. Evol.* **2016**, *33*, 1870–1874. [[CrossRef](#)]
87. Saitou, N.; Nei, M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. *Mol. Biol. Evol.* **1987**, *4*, 406–425.
88. Hall, T.A. BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. *Nucleic Acids Symp. Ser.* **1999**, *41*, 95–98.
89. Ludwig, J.; Margalit, T.; Eismann, E.; Lancet, D.; Kaupp, U.B. Primary structure of cAMP-gated channel from bovine olfactory epithelium. *FEBS Lett.* **1990**, *270*, 24–29. [[CrossRef](#)]
90. Chen, C.; Okayama, H. High-efficiency transformation of mammalian cells by plasmid DNA. *Mol. Cell. Biol.* **1987**, *7*, 2745–2752. [[CrossRef](#)]

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).